Patents by Inventor Anne Laure Grillot

Anne Laure Grillot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8426426
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
  • Patent number: 8404852
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Patent number: 8394803
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: March 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Arnaud LeTiran, Yusheng Liao, Emanuele Perola, Steven Ronkin, Dean Stamos, Tiansheng Wang
  • Patent number: 8372873
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: February 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Publication number: 20130030004
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or TopoIV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Application
    Filed: November 6, 2006
    Publication date: January 31, 2013
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Arnaud LeTiran, Yusheng Liao, Emanuele Perola, Steven Ronkin, Dean Stamos, Tiansheng Wang
  • Publication number: 20130023525
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Application
    Filed: April 24, 2012
    Publication date: January 24, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Publication number: 20120202784
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 9, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • Publication number: 20120184512
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.
    Type: Application
    Filed: January 13, 2012
    Publication date: July 19, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Arnaud Le Tiran, Anne-Laure Grillot, Paul S. Charifson, Yousef Laafiret Bennani, Hardwin O'Dowd, Emanuele Perola
  • Publication number: 20120165333
    Abstract: The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders.
    Type: Application
    Filed: April 20, 2011
    Publication date: June 28, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Pan Li, Kira McGinty, Steven M. Ronkin, Qing Tang, Anne-Laure Grillot, Nathan D. Waal
  • Patent number: 8193352
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 5, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Patent number: 8188095
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: May 29, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Publication number: 20120040950
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: December 21, 2010
    Publication date: February 16, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • Publication number: 20120010222
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Patent number: 8067606
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: November 29, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Patent number: 8034832
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: October 11, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Publication number: 20110182856
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
    Type: Application
    Filed: March 29, 2011
    Publication date: July 28, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Amaud Le Tiran, Emanuele Perola
  • Patent number: 7985762
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3—NS4A protease.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: July 26, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Publication number: 20110165120
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
    Type: Application
    Filed: February 28, 2011
    Publication date: July 7, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Patent number: 7964624
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 21, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Publication number: 20110104207
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS